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Abstract
HSJ1 (DNAJB2), a member of the DNAJ family of molecular chaperones, is a key player in neuronal proteostasis maintenance.
It binds ubiquitylated proteins through its Ubiquitin Interacting Motifs (UIMs) and facilitates their delivery to the proteasome
for degradation. Mutations in the DNAJB2 gene lead to inherited neuropathies such as Charcot-Marie-Tooth type-2, distal
hereditary motor neuropathies, spinal muscular atrophy with parkinsonism and the later stages can resemble amyotrophic
lateral sclerosis. HSJ1 overexpression can reduce aggregation of neurodegeneration-associated proteins in vitro and in vivo;
however, the regulation of HSJ1 function is little understood. Here we show that CK2, a ubiquitous and constitutively active
protein kinase, phosphorylates HSJ1 within its second UIM, at the dominant site Ser250 and the hierarchical site Ser247.
A phospho-HSJ1 specific antibody confirmed phosphorylation of endogenous HSJ1a and HSJ1b. A tandem approach of
phospho-site mutation and treatment with CK2 specific inhibitors demonstrated that phosphorylation at these sites is
accompanied by a reduced ability of HSJ1 to bind ubiquitylated clients and to exert its chaperone activity. Our results disclose
a novel interplay between ubiquitin- and phosphorylation-dependent signalling, and represent the first report of a regulatory
mechanism for UIM-dependent function. They also suggest that CK2 inhibitors could release the full neuroprotective poten-
tial of HSJ1, and deserve future interest as therapeutic strategies for neurodegenerative disease.
Introduction
HSJ1 (also known as DNAJB2) is a key component in neuronal
protein quality control. It is a molecular chaperone that is pref-
erentially expressed in neurons that can act as a shuttling factor
to sort chaperone clients to the proteasome (1). DNAJB2 muta-
tions have been identified as causative of hereditary neuropa-
thies. The first finding was in a family with a rare autosomal
recessive distal hereditary motor neuropathy (dHMN) where a
splice site mutation in the DNAJB2 gene was found (2). The phe-
notypic spectrum of DNAJB2-related neuropathies was later
broadened by the discovery of two additional mutations of the
DNAJB2 gene in patients with dHMN and Charcot-Marie-Tooth
disease type 2 (CMT2) (3). A further case of dHMN, parkinsonism
and cerebellar ataxia due to HSJ1 mutation was recently
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reported (4), and a large DNAJB2 gene deletion was found in a
family with recessive spinal muscular atrophy and parkinson-
ism (5).
Two HSJ1 isoforms are expressed in humans, HSJ1a and
HSJ1b, as a result of alternative splicing (6). They share the
same basic domain structure (Fig. 1A), but their intracellular lo-
calization differs: HSJ1a is cytosolic and nuclear, while HSJ1b
has a longer C-terminus and is anchored to the cytoplasmic
face of ER due to C-terminal geranylgeranylation (7). At the N-
terminus, HSJ1 presents the typical J domain of DnaJ (Hsp40)
molecular chaperone family members (8), that stimulates sub-
strate loading onto Hsp70 chaperones (1,9). Near the C-terminus
HSJ1 has two Ubiquitin Interacting Motifs (UIMs), that function
to bind ubiquitin chains and help prevent client protein aggre-
gation. The neuroprotective role of HSJ1 has been demonstrated
in different disease models (10): it suppresses the aggregation of
polyglutamine expanded proteins, significantly enhancing mu-
tant huntingtin solubility in Huntington disease in cells and in
mice (1,11), and promoting misfolded protein targeting to the
ubiquitin-proteasome system (12); HSJ1a cooperates with Hsp70
to promote proteasome-degradation of ataxin-3, a protein re-
sponsible for spinocerebellar ataxia type 3 (SCA3) (13); HSJ1a
prevented the aggregation of the misfolded C289G Parkin, a
Parkinson disease-associated ubiquitin-protein ligase mutant,
and restored its function in mitophagy (14). Interestingly, a pro-
tective function of HSJ1a has also been demonstrated in ALS
models: its overexpression in motor neurons of SOD1G93A mu-
tant transgenic mice was found to improve the disease symp-
toms; the molecular mechanism was related to HSJ1a
association with SOD1, with its consequent increased ubiquity-
lation and reduced aggregation (15). More recently HSJ1a was
shown to be highly effective at preventing the aggregation of
TDP-43 (16). Therefore, HSJ1 functions to regulate the proteaso-
mal targeting of misfolded proteins, and protect neurons
against cytotoxic protein aggregation by the coordinate actions
of its J and UIM domains.
UIMs are sequences of about 20 amino acids, present in pro-
teins belonging to the proteasomal and lysosomal protein deg-
radation systems, where they confer the ability to bind mono-
and/or poly-ubiquitylated proteins (17). A conserved sequence
has been identified on UIMs as the minimal consensus for the
Ub-binding function (18). This sequence includes a Serine resi-
due followed by an acidic residue three positions downstream.
We noticed that this motif is superimposable to the consensus
sequence for the recognition and phosphorylation by protein ki-
nase CK2 (Fig. 1B). CK2 is an acidophilic kinase that prefers Ser/
Thr sites surrounded by numerous acidic residues. Its consen-
sus sequence is one of the most specific and well-defined
amongst protein kinases (19,20): the minimal requirement is ex-
actly represented by an acidic determinant at positionþ3 down-
stream to the target site. CK2 is a highly pleiotropic and
constitutively active enzyme mainly present in cells as a tetra-
mer, composed of two catalytic (a and/or a’) and two regulatory
(b) subunits. It phosphorylates hundreds of substrates (21) and
controls many cellular processes, but its major recognized func-
tion is in counteracting apoptosis (22–24). Although present in
all cells, CK2 is overexpressed in cancers, and is currently con-
sidered a valuable target in anticancer therapies (25). However,
the multi-faceted profile of CK2 points for its involvement in a
broader range of human diseases, such as neurodegeneration,
where its importance has been already suggested, although
never studied in detail.
Here we investigate the connection between CK2 and HSJ1
as a paradigmatic example of functional cross-talk between the
phosphorylation and ubiquitin dependent signalling, based on
the working hypothesis that phosphorylation of the serines
conforming to the CK2 consensus on the HSJ1 UIM2 may affect
its ability to bind ubiquitylated proteins.
Results
HSJ1 phosphorylation by CK2
To test the hypothesis that HSJ1 is phosphorylated by CK2, we
first analysed in vitro phosphorylation with recombinant human
HSJ1a as substrate in radioactive phosphorylation assays. In the
presence of monomeric CK2 (a catalytic subunit) or CK2 holoen-
zyme (a2b2), we observed a remarkable phosphorylation (Fig. 2A)
that was concentration and time dependent (Fig. 2B). As ex-
pected, the other HSJ1 isoform, HSJ1b, which shares the same
CK2 putative sites with HSJ1a, was also readily phosphorylated
Figure 1. CK2/UIM consensus and HSJ1 structure organization. (A) The consensuses for phosphorylation by CK2 (19,20) or for Ub-protein binding by UIM (18) are shown.
The overlapping segments are boxed. (B) The domains organization of the two HSJ1 isoforms are shown as in (1,54). The sequence of UIM2 is also reported, highlighting
the CK2 putative sites.
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by CK2 in vitro (Fig. 2C). The two isoforms of the CK2 catalytic
subunits, a and a’, had a similar activity towards HSJ1 (Fig. 2C).
To confirm HSJ1 phosphorylation in the cellular milieu, we
transiently expressed myc-tagged HSJ1a in HEK-293T cells, and
performed HSJ1 immunoprecipitation after cell loading with
[32P]phosphate to generate an intracellular pool of radioactive
ATP. The autoradiography analysis of the immunoprecipitates
confirmed that HSJ1 undergoes phosphorylation in cells (Fig.
2D); moreover, we observed a strong reduction of phosphate in-
corporation upon cell treatment with the CK2 specific inhibitor
CX-4945 (26), suggesting that CK2 is a prominent HSJ1 phos-
phorylating kinase.
Identification of HSJ1 phospho-site(s)
In order to identify the precise phosphorylated residue(s) in
HSJ1, HSJ1a was phosphorylated in vitro by CK2, digested with
V8 protease and the proteolytic peptides analysed by mass
spectrometry (MS/MS). This identified Ser247, Ser250, and
Ser264 as phospho-amino acids (Supplementary Materials,
Table S1 and Fig. S1).
To validate these findings, we produced Ser-to-Ala single-
site mutants of all the identified sites, and also the putative ad-
ditional CK2 site Ser262 within the second UIM, although it was
not identified by MS/MS. In vitro phosphorylation of the recom-
binant purified HSJ1a mutants was consistent with the MS out-
comes (Fig. 3A), supporting the view that Ser262 is not affected;
Ser264 very weakly contributes to the overall phosphorylation,
while Ser250 appears to be the main phosphorylation site, as its
substitution almost completely abrogated phosphorylation. A
little surprisingly, Ser247 mutation to Ala caused an about 50%
drop on the total HSJ1a radioactivity. A plausible explanation is
that although Ser247 does not fulfill the CK2 minimal consensus
sequence, because it does not have an acidic residue inþ3
Figure 2. HSJ1 phosphorylation by CK2 in vitro and in cells. (A) Different amounts of recombinant HSJ1a were incubated with a radioactive phosphorylation mixture in
the presence of CK2 a2b2 (50 ng) or a (50 ng), as indicated. Casein was used as a control substrate for CK2 activity. (B) Phosphorylation of HSJ1 by a CK2 (50 ng) was per-
formed for increasing times (upper panel, 0.5 mg HSJ1) or with increasing HSJ1 amount (lower panel, 5 min incubation). The radioactivity is shown. (C) Different amounts
of recombinant HSJ1a or HSJ1b were phosphorylated by CK2 a (50 ng) or a’ (50 ng), as indicated. The radioactivity is shown. (D) HEK-293T cells were transfected with
myc-HSJ1a (þ) or empty vector (), then loaded with (32P)phosphate, and treated with 10mM CX-4945, as indicated. Anti-myc IP was performed, followed by analysis of
radioactivity and of amount of HSJ1a immunoprecipitated. The lower panel (input) shows 20 mg of total protein lysate, analysed by WB for HSJ1 before IP. Radioactive
phospho-proteins were separated by SDS-PAGE or SDS-PAGE/blot and analysed for radioactivity using Cyclone Plus (PerkinElmer), or by Coomassie blue staining, or by
WB, as indicated in each panel. Representative experiments are shown.
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position, once Ser250 is phosphorylated the residue becomes
acidic and fits the consensus sequence. This implies that a hier-
archical phosphorylation can occur in HSJ1, where the previous
phosphorylation of Ser250 primes Ser247 for subsequent phos-
phorylation. This hypothesis was supported by synthetic pep-
tides reproducing the HSJ1 sequence 244–254 in two variants,
differing by the presence or absence of phosphate at Ser250. As
shown in Fig. 3B, both peptides are readily phosphorylated by
CK2, with a superiority of the one presenting both Ser247 and
Ser250 as available sites.
The results obtained in vitro with the recombinant mutants
were confirmed in cells: expression of the mutants in HEK-293T
followed by their immunoprecipitation from [32P]phosphate
pre-loaded cells, revealed that the Ser250Ala mutant was not
phosphorylated, demonstrating that this site is the critical resi-
due for the phosphorylation of the HSJ1 protein (Fig. 3C).
HSJ1 phospho-specific antibodies
Collectively, these data indicate that there are two major
phospho-sites in the HSJ1 protein, at Ser250 and Ser247, with
a minimal contribution of other sites. We therefore decided
to produce phospho-specific antibodies towards these sites,
choosing a strategy that allows the detection of the protein
either when mono-phosphorylated on Ser250 or bi-phosph
orylated at Ser250 and Ser247. The antibodies were first
validated in vitro toward the protein phosphorylated by recom-
binant CK2 (Fig. 4A), and by Surface Plasmon Resonance (SPR)
experiments, these data show a high affinity for the mono-
phosphorylated pSer250 peptide, while a bis-phosphorylated
peptide reproducing pSer247/pSer250 sequence was more
poorly recognized (Supplementary Material, Fig. S2A). Then we
used the phospho-specific antibodies to assess the HSJ1 phos-
phorylation in cells. First, we expressed either the wild-type
(WT) protein or the Ser250 mutant (S250A) of HSJ1a or b in HEK-
293T cells. The WT protein was strongly detected by the
phospho-specific antibody, while the mutation of Ser250 com-
pletely abrogated the signal (Fig. 4B). A major decrease in the
phospho-antibody signal was observed in cells expressing WT
HSJ1a and treated with a panel of CK2 inhibitors (Fig. 4C). The
strong reduction in HSJ1 phosphorylation in response to CX-
4945 or CX-5011 (27) was less evident with TBB, but was consis-
tent with the reduction of immunoreactivity for the well-known
CK2 target Akt pSer129 (28), or even more pronounced.
Furthermore, staurosporine, which inhibits most protein
kinases, but not CK2 (29), had no effect on pHSJ1 imm
unoreactivity.
Then we tested the phospho-HSJ1 antibodies on a CHO cell
line with inducible HSJ1 overexpression. In this case we also ob-
served a significant level of phosphorylation, which was sensi-
tive to CK2 inhibition (Fig. 4D). As expected, the removal of the
inhibitor rapidly restored the HSJ1 phosphorylation, due to the
Figure 3. Phosphorylation of HSJ1 WT and mutants by CK2. (A) Recombinant WT or mutant HSJ1 proteins were phosphorylated by CK2 a2b2 (25 ng) and separated by
SDS-PAGE. Radioactivity and Coomassie staining are shown of representative experiments. The bar graph shows quantification of radioactive (mean of n¼3 experi-
ments 6 SEM. *P<0.05, **P<0.001, unpaired, two-tailed, Student’s t-test). (B) Increasing concentrations of the indicated peptides were phosphorylated by CK2 a2b2
(25 ng) and analysed for the incorporated radioactivity. More details under Materials and Methods. (C) anti-myc IP was performed from lysates of HEK-293T cells trans-
fected with myc-HSJ1a WT or mutants, or empty vector (), pre-loaded with [32P]phosphate. The radioactivity and the amount of HSJ1a in immunoprecipitates and in
total lysates (20mg) are shown (representative experiments). (D) Bar graph shows quantification of radioactive bands of experiments as in panel C, normalized to the
amount of immunoprecipitated HSJ1a (mean of n¼4 experiments 6 SEM. ***P0.001, unpaired, two-tailed, Student’s t-test).
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short half-life of the CX4945-CK2 complex, as recently
described (30).
To assess if phosphorylation also occurs on endogenous
HSJ1, we used human fibroblasts that have been reported to ex-
press detectable levels of endogenous HSJ1 (2,3). We found that
endogenous HSJ1 was phosphorylated in a CK2-dependent
manner, as judged by anti-phospho-HSJ1 reactivity and sensi-
tivity to CK2 inhibition (Fig 4E).
Effects of phosphorylation on HSJ1 function
To test the hypothesis that phosphorylation of HSJ1 could alter
its subcellular localization, as reported for the Ub-binding pro-
tein ataxin-3 (31), immunofluorescence analysis was performed
with the phospho-HSJ1 antibodies on myc or GFP tagged HSJ1 in
the neuronal cell line SK-N-SH; however, we observed a very
similar pattern for total HSJ1a or phospho-HSJ1a signal (Fig. 5).
Furthermore, transfection of the Ser250Ala instead of WT HSJ1
did not alter the localization observed with a pan-HSJ1 antibody,
while abrogating the phospho-specific signal (Fig. 5A). In all
cases the HSJ1a signal was predominantly in the cytosol and
nucleus, as previously reported (7). Even in the case of HSJ1b,
mutation of the phosphorylation site did not alter the
localization of the WT protein, which was consistent with its
published localization on the cytoplasmic face of the ER (7) (Fig.
5B). The lack of effect of phosphorylation on subcellular HSJ1 lo-
calization was also confirmed by treatment of HSJ1-inducible
cells with CX-4945, which had no overt effect (Fig. 5C).
These data show that HSJ1 is phosphorylated within its sec-
ond UIM domain, and that CK2 is the main responsible kinase.
The second UIM domain of HSJ1 has been reported to be the
most important in the binding of ubiquitylated proteins (1),
therefore we wanted to test the hypothesis that the phosphory-
lation could alter HSJ1 client protein recognition (1). Co-
immunoprecipitation was used to analyse the amount of HSJ1a-
associated ubiquitylated-proteins (Ub-proteins) and how this
was affected by HSJ1 phosphorylation state. Initially, we as-
sessed the effect of CK2 inhibition on HSJ1a stable-inducible
cells (Fig. 6A): importantly, more Ub-proteins were co-
precipitated with HSJ1a when cells were treated with CX-4945,
which did not change the total amount of Ub-proteins. To test
whether this was due to the reduced HSJ1 phosphorylation or to
other effects of CK2 inhibition, we applied immunoprecipitation
of HSJ1 from HEK-293T cells overexpressing HSJ1a WT or
phospho-mutant forms (Fig. 6B). We also exploited the mutant
of Ser262, which is not a CK2 site, but is known to impair UIM
functionality (1), and therefore was used as negative control.
Figure 4. CK2-dependent HSJ1 phosphorylation detected in vitro and in cells by means of phospho-specific antibodies. (A) Increasing amount of recombinant HSJ1a
were incubated in the absence or in the presence of CK2 a2b2 (25 ng) and a radioactive phosphorylation mixture; samples were analysed by WB with the phospho-spe-
cific antibody or with total HSJ1 antibody. The radioactivity of the bands is also shown. (B) WT or mutant HSJ1 isoforms were expressed in HEK-293T cells. 20mg of total
lysate proteins were analysed by WB with the phospho-specific antibody or with total HSJ1 antibody. (C) HEK-293T cells transfected with WT HSJ1a were treated for 3 h
with the indicated concentrations of kinase inhibitors; 20mg of total lysate proteins were analysed by WB, as indicated. (D) GFP-HSJ1a expression was induced in CHO
cells by 3 mg/ml tetracycline. Where indicated (þ) cells were treated for 3 h with CX-4945; þ/ refers to cells that where incubated with CX-4945 for 3 h, then the inhibitor
was removed and cells incubated for further 3 h before lysis. 20 mg of total lysate proteins were analysed by WB as indicated. HSJ1 expression was detected by means of
anti-GFP WB. (E) 25mg of total protein lysates from human BJ fibroblasts were resolved by SDS-PAGE followed by immunoblotting to assess endogenous HSJ1 phosphor-
ylation. Where indicated, cells were treated for 2 h with CX-4945. WB analyses were performed, as indicated.
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As expected, the Ser262Ala mutant co-precipitated with the
lowest amount of Ub-proteins, the phospho-null mutant
Ser250Ala showed enhanced binding to Ub-clients compared to
WT HSJ1. By contrast, the same site Ser250 mutated to Asp,
which mimics phosphorylation, was similar to WT or even less
effective for Ub-client association, while the Ser247Ala muta-
tion produced an intermediate level of the coIP Ub signal. These
results indicate that the phosphorylation of HSJ1 by CK2 re-
duced its ability to bind ubiquitylated clients.
Finally, we tested the hypothesis that phosphorylation could
affect the HSJ1 chaperone activity. It has been shown that HSJ1
associates with luciferase, and promotes a decrease of the lucif-
erase level/activity in a UIM dependent manner (12). With this
in mind, we expressed luciferase in control (uninduced) cells
and in HSJ1 induced cells, and we treated them with CX-4945.
Luciferase activity was reduced in cells expressing HSJ1a (as ex-
pected with the proteasomal targeting of the enzyme), and this
was further reduced by the presence of the CK2 inhibitor, which
had a negligible effect in cells not expressing HSJ1a (Fig. 7A). We
then compared HSJ1a WT and mutants for their effect on co-
expressed luciferase. Cells expressing the HSJ1 phospho-site
mutants Ser247Ala and Ser250Ala displayed the lowest
luciferase activity, while the phospho-mimetic Ser250Asp mu-
tant produced an effect similar to the WT (Fig. 7B). Collectively,
these data indicate that the phosphorylation by CK2 prevents
the full functionality of the HSJ1 chaperone activity.
Discussion
Aberrant signal transduction is a major cause of human dis-
eases. In healthy conditions, several types of post-translation
modifications are coordinated in a network of interconnections
that is essential to correctly tune a signal. In this frame, an
emerging theme is represented by the multiple connections be-
tween phosphorylation and ubiquitylation/proteostasis (32).
Here we disclose a novel crosstalk between these two signalling
systems, represented by the kinase CK2 and the Ub-binding pro-
tein HSJ1, whose defective function is related to inherited
neuropathies.
CK2 has been frequently connected to protein degradation
pathways. It has a well-defined role in the regulation of cas-
pases, mainly through the phosphorylation of crucial sites in
caspase substrates that become refractory to proteolysis (23).
CK2 involvement in the regulation of other proteolytic
Figure 5. Subcellular localization of HSJ1 and phospho-HSJ1. (A) SK-N-SH cells transfected with myc-HSJ1a WT or Ser250Ala mutant were stained with anti-c-myc or
anti-phospho HSJ1 antibody, as indicated, and detected by the Alexa Fluor 488 secondary antibody. Nuclei were stained with DAPI. (B) SK-N-SH cells transfected with
myc-HSJ1b WT or Ser250Ala (S250A) mutant were stained with anti-c-myc antibody and revealed by the Alexa Fluor 488 secondary antibody. (C) GFP-HSJ1a expressing
CHO cells were treated for 3 h with 10 mM CX-4945 and analysed for fluorescence localization. Scale bars ¼ 50mm.
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pathways has been also reported. Interestingly, it has been
demonstrated that the SUMO interacting motifs (SIMs), when
phosphorylated by CK2, display a higher affinity for the Ub-like
molecule SUMO. This was initially reported for the tumour
suppressor PML, the exosome component PMSCL1, and the E3
SUMO ligase PIAS1 (33), and recently for the RAP80 protein, a
key component of double-strand DNA break repair mediated by
the BRCA1 complex (34). CK2 also phosphorylates p62, an
Figure 6. Effects of HSJ1 phosphorylation on Ub-client binding. (A) 1 mg of protein lysates from CHO cells stably transfected with HSJ1 (þ) or not (-) were used for HSJ1
immunoprecipitation. Where indicated, cells were treated with 10 mM CX-4945 for 3 h before lysis. 20mg lysate proteins were loaded for input analysis. Mw marker mi-
grations are indicated on the right. # indicates immunoglobulin bands. Bar graph shows the quantification of the Ub signals assigning 100 to the signal of Ub-proteins
co-IP with WT HSJ1. Data are presented as mean of n¼3 experiments 6 SEM. *P<0.05, unpaired, two-tailed, Student’s t-test. (B) HEK-293T cells were transiently trans-
fected with empty vector () or HSJ1 WT or mutants, as indicated; 600 mg proteins from cell lysate were used for HSJ1 immunoprecipitation. Analysis was performed by
WB for Ubiquitin and for HSJ1. # indicates immunoglobulin bands. Mw marker migrations indicated on the left refer to the most left panel, on the right to the three
right panels. Bar graphs shows the quantification of the Ub signals assigning 100 to the signal of Ub-proteins co-IP with WT HSJ1. Data are presented as mean of n¼4 ex-
periments6 SEM. *P<0.05 **P<0.01 ***P<0.001, n.s., not significant, unpaired, two-tailed, Student’s t-test.
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autophagy-related Ub-binding protein; the phosphorylation oc-
curs at several sites, also within the UBA (Ub-associated) do-
main of p62, and promotes a shift of specificity that allows the
binding to both K63-linked and K48-linked poly-Ub (35). CK2 has
been also reported to regulate the clearance of misfolded pro-
teins by recruiting them to aggresomes in response to stress
(36). Moreover, the Ub-interacting protein Ataxin-3 was found
phosphorylated by CK2 at several sites; although phosphoryla-
tion did not affect protein interactions, it affected its subcellular
localization and stabilization (31).
To the best of our knowledge, it has never been reported be-
fore that CK2 phosphorylates a protein within a UIM sequence,
with functional consequences for Ub-client binding. Here we
show that HSJ1, a protein involved in the delivery of Ub-
proteins for proteasomal degradation, is phosphorylated by CK2
on its second UIM, both in vitro and in cells, and this inhibits its
function. Other findings have previously connected CK2 to the
proteasome function. Tsuchiya and coworkers showed that
CK2, by inhibiting the transcriptional activity of Nrf1, down-
regulates the expression of proteasome subunit genes, and that
CK2 knockdown alleviates the accumulation of Ub-proteins
upon proteasome inhibition (37). Moreover, CK2 controls the
stability of 26S proteasome by phosphorylating the 20S protea-
some alpha subunit C8 (38). A recent proteomics study from our
laboratory showed that cell treatment with the CK2 inhibitor
quinalizarin is accompanied by a dramatic increase of all
the components of the proteasomal catalytic core (39). Other
studies have correlated the activity of CK2 to the proteasomal
degradation of specific proteins. It is worth mentioning the di-
rect phosphorylation of PML by CK2 at Ser517, which promotes
the proteasome-dependent degradation of PML, thus preventing
its tumour-suppressive activity (40). More recently, it was dem-
onstrated that the SUMOylation of PML is required for its inter-
action with CK2 and subsequent proteasome-mediated
degradation (41). PTEN is another tumour suppressor protein
degraded by proteasome and phosphorylated by CK2; in
this case, the phosphorylation protects the protein from degra-
dation, although, at the same time it inhibits its function
(42). Similarly, Pax7, a transcription factor with important
functions in muscle regeneration, is protected from
proteasome-dependent degradation when phosphorylated by
CK2 (43).
Here we add HSJ1 to the list of the CK2 targets that are re-
lated to the proteasome function. We identified the HSJ1 sites
where phosphorylation occurs by a hierarchical mechanism,
and demonstrated that the presence of phosphate within the
second UIM of HSJ1 reduces its binding to Ub-clients and its
chaperone activity, without affecting the protein subcellular
distribution. The identification of CK2 as the main HSJ1 phos-
phorylating agent was confirmed not only by the perfect match
of the sites to the CK2 consensus, but also by the observation
that different structurally unrelated CK2 inhibitors prevented
phosphorylation.
Interestingly, the HSJ1 CK2 sites in UIM2 are conserved
amongst different species (Supplementary Material, Fig. S3), al-
though in mouse Ser247 is replaced by a His, and in two other
cases Ser250 is replaced by acidic residues. At present, we do
not know the exact contribution of each of these sites to the
overall phosphorylation of human HSJ1 in vivo, although the in
vitro analysis suggests a balance of 50% between S247 and S250.
The presence of phosphorylatable residues at both Ser247 and
Ser250 positions could be interpreted as an adaptive device, rep-
resenting a mechanism to fine tune the function of UIM2. Our
results obtained with separate mutations (Figs 6B and 7B) dis-
close only minimal differences on HSJ1 function. Ser250-to-Ala
mutation also prevents Ser247 hierarchical phosphorylation,
while in Ser247Ala mutant Ser250 is still phosphorylated; hence,
the similar effects observed with the two mutants suggest a
prominent functional role to Ser247. However, future analysis
will be necessary to discriminate the full impact of each of these
sites.
The effects of UIM phosphorylation in HSJ1 is the opposite of
what reported for the SIM, where the CK2-dependent phosphor-
ylation enhances the affinity for SUMO (33,34), and for UBA, the
Ub-binding domain of p62 that increases its affinity for clients
when phosphorylated by CK2 (beside displaying altered specific-
ity) (35). However, the binding of SUMO to SIM (44), and of Ub to
UBA (45) are due to a combination of hydrophobic and electro-
static interactions, while Ub typically interacts to UIMs mainly
through hydrophobic bonds (46,47). It should be also considered
Figure 7. Effects of HSJ1 phosphorylation on its chaperone activity. (A) Luciferase was expressed in HSJ1 stable transfected CHO cells; HSJ1 expression was induced as
indicated. Where indicated, cells were treated for 3 h with 10mM CX-4945. (B) SK-N-SH cells were co-transfected with HSJ1 WT or mutants and luciferase before activity
measurements. Data are presented as mean of n¼4 (A) or n¼3 (B) replicates 6 SEM. Statistical significance was determined by unpaired, two-tailed, Student’s t-test.
*P<0.05; **P<0.01, n.s., not significant.
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that p62 is phosphorylated in many other sites that can modu-
late the final outcome.
The complex correlation between Ub-binding and phosphor-
ylation is further highlighted by the observation that phosphor-
ylation of ataxin-3 produces variable effects, depending on the
UIM domain considered (31). Further studies will be necessary
to fully understand the functional effects of HSJ1 phosphoryla-
tion by CK2 and the exact mechanism of UIM regulation.
The addition of HSJ1 among the numerous CK2 substrates
has a relevance to neurodegenerative diseases. The importance
of CK2 to neuronal functions and disease is supported by sev-
eral findings. Already in 2000, Blanquet and colleagues reviewed
data supporting a potential role of CK2 in neuronal function and
implicated it in degenerative disorders (48) and this was ex-
tended later (49). More recently, it was found that CK2 phos-
phorylates and promotes stabilization and aggregation of
ataxin3 (ATXN3), the pathogenic protein of spinocerebellar
ataxia type 3 (SCA3) (31). HSJ1, here identified as a novel CK2
substrate, is related to protein aggregation and neurodegenera-
tion, since it exerts a neuroprotective function by processing
aggregation-prone proteins and promoting their delivery to the
proteasome (1), preventing the seeding of aggregation (11) or
refolding of mutant proteins (14,16). Our results, showing that
CK2 inhibits HSJ1 function, suggest that CK2 inhibition might
help enhance HSJ1 function in the clearance of Ub-protein ag-
gregates and deserve attention in a therapeutic perspective.
CK2 inhibitors, already under investigation as anticancer drugs,
might in future also be applied to neurodegenerative conditions
to prevent or reduce protein aggregation. Overexpression of
HSJ1a has been shown to be protective in several models of neu-
rodegeneration both in cells and in vivo by UIM dependent
mechanisms (11,15). Our data suggest that simultaneous HSJ1a
overexpression and CK2 inhibition could synergise the chaper-
one activity and further prolong neuronal survival.
In future, it will be worth investigating whether a competi-
tion occurs between Ub-proteins and CK2 for the recognition se-
quence on HSJ1 UIM2. This could mean that, under conditions
where Ub-proteins tends to accumulate and an intense activity
of HSJ1 is required, Ub-proteins mask the CK2 sites and prevent
their phosphorylation, thus ensuring HSJ1 high efficacy. On the
other hand, whenever CK2 is abnormally high, as usually occurs
in cancer, it could prevail and block the regular clearance of Ub-
proteins by HSJ1. This also suggests that a CK2-mediated link
might exist between cancer and neurodegenerative diseases,
and that any imbalance between CK2 expression and the ma-
chinery represented by HSJ1/Ub-clients/proteasome could be
detrimental.
The focus of this work was HSJ1; however, UIMs are well-
conserved domains, present in several proteins with diverse
functions; we have preliminary results showing that indeed
CK2 efficiently phosphorylates other UIM-containing proteins.
Future work will be dedicated to understand whether CK2-
mediated phosphorylation might be a general mechanism for
regulating their functions; it is also conceivable that protein-
specific elements contribute to modulate the effects of UIM
phosphorylation, thus adding further complexity to the inter-
section between CK2 and Ub signalling.
Materials and Methods
Antibodies
Anti-CK2 a was raised in rabbit against the sequence of the hu-
man protein at C-terminus [376–391], as previously described
(50), anti-CK2 b was from Abcam; anti-pSer129 Akt was either
produced in rabbit as in (28) or purchased from Abcam, anti-
total Akt and anti-total HSJ1 were from Santa Cruz
Biotechnologies, anti-myc, anti-tubulin and anti-actin from
Sigma; anti-mono/poly-ubiquitinylated conjugates was from
Enzo Life Sciences. Anti-pHSJ1 were produced in rabbits, as de-
scribed below, and characterized as in Fig. 2 and Supplementary
Material, Fig. S2.
Protein purification
Human His-tagged HSJ1 WT and mutants cloned in pET-14b
vectors were used to transform E. coli BL21(DE3) strain. The bac-
terial culture was grown to reach an Optic Density (OD) of 0.3–
0.4 when protein synthesis was induced for 4 h by 100 mM
Isopropil-b-D-1-tiogalattopiranoside (Sigma-Aldrich). Bacteria
were then harvested by centrifugation and sonicated in bacte-
rial lysis buffer (50 mM NaH2PO4 pH 8, 100mM NaCl, 0.01%
Tween-20 and 2 mM DTT). Cell debris were discarded by centri-
fugation (35000 x g, 10 min) and HSJ1 was purified from the su-
pernatant by His-selective affinity resin (Sigma-Aldrich) and
eluted with 300 mM imidazole pH 8. Aliquots of the purified pro-
teins were stored at 80C in 10% glycerol, 2 mM DTT.
In vitro phosphorylation assays of HSJ1 proteins and
peptides
Recombinant purified human HSJ1 or peptides were incubated
for 10min at 30C with recombinant CK2 and [c-33P] ATP in an
appropriated phosphorylation buffer (50 mM Tris–HCl pH 7.5,
10 mM MgCl2, 50 mM [c-P
33] ATP at 2000 cpm/pmol (PerkinElmer)
and 0.1 M NaCl). Phospho-reactions were stopped spotting pep-
tides onto phospho-cellulose papers (Perkin Elmer) or by adding
Laemmli buffer. Proteins were resolved onto SDS-PAGE, stained
with Coomassie blue and analysed by digital autoradiography
(CyclonePlus Storage Phosphor System, PerkinElmer).
HSJ1 phospho-sites identification
Phospho-HSJ1 digestion
Recombinant HSJ1 was incubated with recombinant CK2 for
60 min at 30C in a phosphorylation buffer suitable for the sub-
sequent protein digestion (Phosphate Buffer pH 7.8, 10 mM
MgCl2, 50 mM ATP and 0.1M NaCl). Disulfide bonds were then re-
duced by 5mM DTT for 30 min at 60C followed by alkylation
with 15mM iodoacetamide for 15 min at room temperature.
Finally, the final volume was brought to 50 mL and HSJ1 was di-
gested overnight at 37C by Glu-C protease (Promega) as from
manufacturer’s instruction. The reaction was then sent to mass
spectrometry analysis.
Phosphopeptides enrichment and LC-MS/MS analysis
Enrichment of phosphorylated peptides was carried out as re-
ported in (51). Briefly, samples were subjected to a phosphopep-
tide enrichment step using home-made TiO2 micro-columns
and analysed by LC-MS/MS using a LTQ-Orbitrap XL mass spec-
trometer (ThermoFisher Scientific) coupled on-line with a nano-
HPLC Ultimate 3000 (Dionex – ThermoFisher Scientific). Samples
were loaded onto a 10 cm pico-frit column (75lm I.D., 15 lm tip;
New Objective) packed with C18 material (Aeris Peptide 3.6 lm
XB-C18, Phenomenex) and separated using a 45 min linear gra-
dient of ACN/0.1% formic acid (from 0% to 40% ACN in 25 min),
at a flow rate of 250 nL/min. To increase phosphopeptides
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identification confidence, every sample was analysed three
times with three different fragmentation methods (MS2, MS3,
and MultiStage Activation), as detailed in (51).
Raw data files were analysed with a MudPit protocol against
the Human section of the Uniprot database (version 20150107,
89706 sequences) with the software Proteome Discoverer 1.4
(ThermoFisher Scientific) interfaced to a Mascot search engine
(version 2.2.4, Matrix Science). Enzyme specificity was set to
V8-DE with up to 3 missed cleavages. Mass tolerance window
was 10 ppm for parent mass and 0.6 Da for fragment ions.
Carbamidomethylation of cysteine was set as fixed modifica-
tion. Oxidation of methionine residues and phosphorylation of
serine, threonine, and tyrosine were set as variable modifica-
tions. The algorithm PhosphoRS (52) was used to help in the as-
signment of the correct phosphorylation sites. False Discovery
Rate (FDR) was calculated by Proteome Discoverer based on
the search against the corresponding randomized database.
Phosphopeptides identified with high (99%) confidence, were
manually inspected for sequence and phosphorylation site
confirmation.
Site-directed mutagenesis
HSJ1 mutations were introduced by site-directed mutagenesis
with the QuikChange II Site-Directed Mutagenesis Kit (Agilent
Technologies) in accordance with the manufacturer’s protocol.
Mammalian and bacterial vectors for human HSJ1 were as in
(1,7). Custom-made primers were made by Sigma-Aldrich.
Cell culture and treatments
All cells were cultured in an atmosphere containing 5% CO2;
HEK293T (human embryonic kidney) cells and CHO (Chinese
hamster ovary) cells were maintained in DMEM (Sigma), human
BJ fibroblasts (ATCC, CRL-2522) in DMEM plus non-essential
amino acids (Sigma) and SK-N-SH (human neuroblastoma) cells
in DMEM/F-12 1:1 nutrient mixture (Sigma); media were supple-
mented with 10% (v/v) fetal bovine serum (FBS, Sigma), 2 mM
L-glutamine (Sigma), 100 U/mL penicillin, and 100 mg/mL strep-
tomycin (Sigma). Cell treatments with inhibitors were per-
formed in the culture medium. Control cells were treated with
equal amounts of the inhibitor solvent, which never exceeded
0.5% (v/v).
CX-4945 (Cylene Pharmaceuticals), CX-5011 (Glixx
Laboratories), and TBB (kindly donated by Dr. Z. Kazimierczuk,
Warsaw, Poland) were all dissolved in 10 mM stock solutions in
DMSO (Sigma).
Cell transfection, lysis and immunoprecipitation
Transient expression of HSJ1 WT and mutants was induced by
transfecting CMV-Myc-Tag3a vectors into mammalian cell lines.
Cells were plated into 6-well plates (2.5 105 cells/well) the day
before transfection and grown to about 70% confluence. HEK-
293T cells were transiently transfected with 1 lg of plasmids by
a standard calcium-phosphate procedure. The transfection mix-
ture was removed after 16 h and cells were collected 48 h after
transfection. Similarly, SK-N-SH cells were transiently trans-
fected either on plates or 8-wells Permanox microscope slides
(Sigma-Aldritch) with 1 lg of plasmids using Lipofectamine LTX
Reagent (Life technologies) accordingly to the manufacturer’s
protocol. 48 h after transfection cells were collected or slides
fixed for ICC analysis.
Cells were lysed with an ice-cold buffer containing 20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.5%
(v/v) Triton X-100, 2 mM dithiothreitol (DTT), protease inhibitor
cocktail complete (Roche), 10 mM NaF, 1 lM okadaic acid (Enzo
Life Sciences), and 1 mM Na vanadate. After 60 min incubation
on ice, the lysates were centrifuged at 16000 x g for 30 min,
at 4C and the supernatants were subjected to the Bradford
quantification assay before SDS-PAGE separation and western
blot analysis.
32P[phosphate] cell labelling
HEK-293T cells were transfected with HSJ1 WT and mutants by
a standard calcium phosphate protocol as described above. 44 h
after transfection cells were washed twice with PBS (Sigma) and
incubated with phosphate-free DMEM (Sigma) supplemented
with 50 mCi/mL of 32P[phosphate] for 3 h. If required, cells were
treated with 10 mM CX-4945 for the same length of time. Cells
were then harvested and lysed before being subjected to (co)im-
munoprecipitation protocol, digital autoradiography and west-
ern blot analysis.
Western blotting
Equal amounts of proteins from cell lysates were analysed onto
11% SDS-PAGE and blotting on PVDF membranes (Immobilon-P
Millipore) using the Lightning Blotter Transfer System (Perkin
Elmer) and buffers as from manufacturer’s instructions. Dried
membranes were then washed with 1% (w/v) bovine serum al-
bumin (Sigma) in TTBS buffer (Tris–HCl 50 mM pH 7.5, NaCl
50 mM, 0.1% Tween-20) and incubated with the indicated anti-
bodies. Membranes were then incubated with secondary HRP-
conjugated antibodies (Perkin Elmer) for 1 h and bands were de-
tected by a chemiluminescence solution composed by 2.25 ml
H2O, 250 ll 1 M Tris, pH 9.35, 1 ll H2O2 and 2.5 ml of a luminol so-
lution (prepared with luminol 78 mg and p-iodophenol 95 mg
dissolved in 100 ml 0.1 M Tris pH 9.35) plus 30% (w/v) BSA.
Finally, bands were visualized with the Kodak Image Station
4400MM PRO and quantified with the Kodak 1D Image software.
Stable transfection
CHO inducible cell lines were produced using the Flp-in T-REx system
by following the manufacturer’s instructions (Thermo-Scientific).
Primer SEQUENCE (5’-3’)
Forward
S247A
GCCTCATGCCCCTTGGACGCCGACCTCTCTGAGGATGAGG
Reverse
S247A
CCTCATCCTCAGAGAGGTCGGCGTCCAAGGGGCATGAGGC
Forward
S250A
CCCCTTGGACAGCGACCTCGCCGAGGATGAGGACCTGCAG
Reverse
S250A
CTGCAGGTCCTCATCCTCGGCGAGGTCGCTGTCCAAGGGG
Forward
S262A
GCAGCTGGCCATGGCCTACGCCCTGTCAGAGATGGAGGC
Reverse
S262A
GCCTCCATCTCTGACAGGGCGTAGGCCATGGCCAGCTGC
Forward
S250D
CCCCTTGGACAGCGACCTCGATGAGGATGAGGACCTGCAG
Reverse
S250D
CTGCAGGTCCTCATCCTCATCGAGGTCGCTGTCCAAGGGG
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eGFP-tagged HSJ1a or HSJ1b in the pcDNA5/FRT/TO was received as a
gift from Prof. HH Kampinga (Groningen; (53)) and used to produce in-
ducible stable cells lines expressing HSJ1 proteins under the control of
tetracyline.
Peptide synthesis
The synthetic peptides PLDSDLSEDED-betaAla-RRR, PLDSDLpSEDED-
betaAla-RRR PLDSDLSEDED-betaAla-C, PLDSDLpSEDED-betaAla-C,
PLDpSDLpSEDED-betaAla-C were synthesized by solid-phase tech-
nique using a multiple peptides synthesizer (SyroII, MultiSynTech
GmbH) on a pre-loaded Wang resin (100–200 mesh) with Fmoc-Ne-
tert-butyloxycarbonyl-L-lysine (Novabiochem). The fluoren-9-ylmet
hoxycarbonyl (Fmoc) strategy was used throughout the peptide chain
assembly, utilizing O-(7-azabenzotriazol-1-yl)-N’,N’,N0,N0-tetramethy-
luronium hexafluorophosphate (HATU) as coupling reagent. The
side-chain protected amino acid building blocks used were: N-a-
Fmoc-Nx-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-argi
nine, N-a-Fmoc-b-tert-butyl-L-aspartic acid, N-a-Fmoc-c-tert-butyl-
L-glutamic acid, N-a-Fmoc-O-tert-butyl-L-serine, N-a-Fmoc-S-tri-
tyl-cystine, and N-a-Fmoc-O-benzyl-phospho-L-serine. Cleavage
of the peptides was performed by incubating the peptidyl resins
with trifluoroacetic acid/H2O/triisopropylsilane (95%/2,5%/2,5%)
for 2.5 h at 0C. Crude peptides were purified by reverse phase
HPLC on a preparative column (Prep Nova-Pak HR C18). Molecular
masses of the peptide were confirmed by mass spectroscopy on a
MALDI TOF-TOF using an Applied Biosystems 4800 mass
spectrometer.
Phospho-antibodies production and purification
Antibodies specific to phospho sites Ser-247 and Ser 250 were
generated. New Zealand rabbits were immunized with the fol-
lowing synthetic peptides (from human HSJ1 sequence [244–
254]) PLDSDLSEDED-betaAla-C, PLDSDLpSEDED-betaAla-C and
PLDpSDLpSEDED-betaAla-C coupled with maleimide-activated
keyhole limpet hemocyanine (KLH) or bovine serum albumin
(BSA) (1:1 w/w) through the C-terminal cysteine. Rabbits were
injected four times at 3-week intervals, with 0,5 mg of peptide-
proteins conjugates emulsified with Freund’s adjuvant (1:1 v/v).
Antisera were purified using an immobilized peptide affinity
resin (Sulfo Link Coupling Gel, Pierce) according to manufac-
turer’s instructions.
Ub-protein binding analysis
Cells were lysed in Co-IP Buffer (25 mM MOPS pH 7.2, 100 mM
KCl, 5mM EDTA, 0.5% Tween-20), then 0.5–1 mg of total protein
lysate was incubated with anti-myc antibody for 2 h followed by
incubation with Protein G PLUS-Agarose resin (Santa Cruz
Biotechnology) for 45 min. The resin was then washed twice
with wash buffer (25 mM MOPS pH 7.2, 100 mM KCl, 5mM EDTA).
Myc-tagged HSJ1 and co-precipitated proteins were eluted with
loading buffer and subjected to gel electrophoresis followed by
western blot analysis with anti-Ub antibody.
Statistical analysis
Statistical analysis was performed with the Software Graphad
Prism and significance determined using the unpaired, two-
tailed, Student’s t-test. All data were collected from at least 3
independent experiments; representative experiments are
shown. Graphs show quantifications, SEM and significances
(*P 0.05, ** P0.01, ***P 0.001).
Immunofluorescence experiments
For immunofluoescence staining, coverslips were washed twice
with PBS and fixed in 4% paraformaldehyde for 10 min. Cells
were then permeabilized with 0.5% Triton X-100 for 10 min, at
room temperature. Then, microscope slides were incubated in
blocking buffer (3% bovine serum albumin (BSA) and 10% nor-
mal donkey serum in PBS) for 1 h before incubation with pri-
mary antibodies for 1 h at room temperature. Species-specific
anti-IgG Alexa Fluor 488 secondary antibodies were used and
nuclei were stained with DAPI (Sigma). Slides were mounted
with fluorescence mounting medium (Dako) and images were
acquired with the 63X objective of Zeiss LSM700. Scale bars are
50 mM.
Luciferase assay
SK-N-SH cells were seeded in 96-well plates and transfected at
80% confluence with TransIT-LT1 Transfection Reagent (Mirus).
Each well was transfected with 20 ng of HSJ1 WT and mutants,
and 10 ng of the pBK-CMV, a cytomegalovirus (CMV)-promoter-
driven firefly luciferase reporter vector.
Luciferase was expressed in stably HSJ1-transfected CHO
cells as described above. HSJ1 synthesis was induced 3 h post
transfection by 3 mg/ml tetracycline (Invitrogen). If required,
after 21 h cells were treated with 10 mM CX-4945. 24 h after
transfection, luciferase activity was measured on an Orion L
Microplate Luminometer (Titertek Berthol) with a dual-
luciferase reporter assay system (Dual-Glo Luciferase Assay
System, Promega) in accordance with the manufacturer’s
protocol.
Supplementary Material
Supplementary Material is available at HMG online.
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